Literature DB >> 33558253

Resistant Hypertension in CKD.

George Thomas1, Mahboob Rahman2.   

Abstract

Entities:  

Keywords:  blood pressure; chronic kidney disease; hypertension

Mesh：

Substances：

Year:  2021        PMID： 33558253      PMCID： PMC8011006          DOI： 10.2215/CJN.14610920

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

Review 1.  Automated office blood pressure.

Authors:  Martin G Myers; Marshall Godwin
Journal:  Can J Cardiol       Date:  2012-01-20       Impact factor: 5.223

2.  Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.

Authors:  Michael E Ernst; Barry L Carter; Chris J Goerdt; Jennifer J G Steffensmeier; Beth Bryles Phillips; M Bridget Zimmerman; George R Bergus
Journal:  Hypertension       Date:  2006-01-23       Impact factor: 10.190

3.  Combined angiotensin inhibition for the treatment of diabetic nephropathy.

Authors:  Linda F Fried; Nicholas Emanuele; Jane H Zhang; Mary Brophy; Todd A Conner; William Duckworth; David J Leehey; Peter A McCullough; Theresa O'Connor; Paul M Palevsky; Robert F Reilly; Stephen L Seliger; Stuart R Warren; Suzanne Watnick; Peter Peduzzi; Peter Guarino
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

Review 4.  Thiazides in advanced chronic kidney disease: time for a randomized controlled trial.

Authors:  Arjun D Sinha; Rajiv Agarwal
Journal:  Curr Opin Cardiol       Date:  2015-07       Impact factor: 2.161

5.  Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.

Authors:  George Thomas; Dawei Xie; Hsiang-Yu Chen; Amanda H Anderson; Lawrence J Appel; Shirisha Bodana; Carolyn S Brecklin; Paul Drawz; John M Flack; Edgar R Miller; Susan P Steigerwalt; Raymond R Townsend; Matthew R Weir; Jackson T Wright; Mahboob Rahman
Journal:  Hypertension       Date:  2015-12-28       Impact factor: 10.190

6.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

7.  Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Rajiv Agarwal; Patrick Rossignol; Alain Romero; Dahlia Garza; Martha R Mayo; Suzette Warren; Jia Ma; William B White; Bryan Williams
Journal:  Lancet       Date:  2019-09-15       Impact factor: 79.321

Review 8.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 9.897

9.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.